American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19
Background: Coronavirus disease 2019 (COVID-19)–related critical illness and acute illness
are associated with a risk of venous thromboembolism (VTE). Objective: These evidence …
are associated with a risk of venous thromboembolism (VTE). Objective: These evidence …
Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report
Background This is the 2nd update to the 9th edition of these guidelines. We provide
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …
[HTML][HTML] Epidemiology and prevention of venous thromboembolism
Venous thromboembolism, that consists of the interrelated conditions deep-vein thrombosis
and pulmonary embolism, is an under-appreciated vascular disease. In Western regions …
and pulmonary embolism, is an under-appreciated vascular disease. In Western regions …
Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report
Background This is the 2nd update to the 9th edition of these guidelines. We provide
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …
Genome-wide meta-analysis identifies 93 risk loci and enables risk prediction equivalent to monogenic forms of venous thromboembolism
We report a genome-wide association study of venous thromboembolism (VTE)
incorporating 81,190 cases and 1,419,671 controls sampled from six cohorts. We identify 93 …
incorporating 81,190 cases and 1,419,671 controls sampled from six cohorts. We identify 93 …
[HTML][HTML] Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of …
Background Due to the bleeding risk of full-dose systemic thrombolysis and the lack of major
trials focusing on the clinical benefits of catheter-directed treatment, heparin …
trials focusing on the clinical benefits of catheter-directed treatment, heparin …
American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing
S Middeldorp, R Nieuwlaat… - Blood …, 2023 - ashpublications.org
Background Hereditary and acquired thrombophilia are risk factors for venous
thromboembolism (VTE). Whether testing helps guide management decisions is …
thromboembolism (VTE). Whether testing helps guide management decisions is …
Direct oral anticoagulants versus warfarin in the treatment of cerebral venous thrombosis (ACTION-CVT): a multicenter international study
Background: A small randomized controlled trial suggested that dabigatran may be as
effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to …
effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to …
Pharmacology of heparin and related drugs: An update
J Hogwood, B Mulloy, R Lever, E Gray, CP Page - Pharmacological reviews, 2023 - ASPET
Heparin has been used extensively as an antithrombotic and anticoagulant for close to 100
years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence …
years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence …